Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Oct 2017

Volume: 18

Issue: 10

Affiliations

[1 ] Asbestos Diseases Research Institute, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia. Electronic address: nico.vanzandwijk@sydney.edu.au.

[2 ] Northern Cancer Institute, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[3 ] Asbestos Diseases Research Institute, Sydney, NSW, Australia; Chris O'Brien Lifehouse, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[4 ] Department of Oncology, Concord Repatriation General Hospital, Sydney, NSW, Australia.

[5 ] Chris O'Brien Lifehouse, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[6 ] Asbestos Diseases Research Institute, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[7 ] Department of Molecular Imaging (PET and Nuclear Medicine), Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[8 ] Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia; Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.

[9 ] Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia.

[10 ] Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

[11 ] Department of Radiology, Concord Repatriation General Hospital, Sydney, NSW, Australia.

[12 ] EnGeneIC, Sydney, NSW, Australia.

Article

Publisher Item ID: S1470-2045(17)30621-6

DOI: 10.1016/S1470-2045(17)30621-6

PubMed ID: 28870611

SO-VID: a6879546-0b90-4d2b-924e-e0b9f12cc01f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 291

See all cited by

- Version 1